1 documents found
Information × Registration Number 0224U033461, (0123U100824) , R & D reports Title Determining the safety of the innovative analgesic propoxazepam in its chemical and biological interactions with other drugs in polytherapy popup.stage_title 2. Визначення хімічних та фізико-хімічних властивостей субстанції пропоксазепаму, необхідних для інтерпретації фармацевтичної взаємодії. Head Holovenko Mykola Ya., Доктор біологічних наук Registration Date 27-12-2024 Organization Physico-Chemical Institute O. Bogatsky National Academy of Sciences of Ukraine popup.description1 Experimental study of the possible interaction of propoxazepam with other drugs in the conditions of polytherapy in order to confirm the safety of the drug popup.description2 The conducted studies studied the interaction of propoxazepam at the pharmaceutical, pharmacokinetic and pharmacological levels. The absence of significant pharmaceutical interactions at the absorption stage was established. Propoxazepam is well tolerated after a single dose (5 mg), has rapid absorption and slow excretion. Oxidized metabolites and their glucuronides are excreted in the urine in a total amount of up to 10.5% of the administered dose, which indicates a high level of metabolism. According to the results of studies of inhibition of various isoforms of cytochrome CYP 450, propoxazepam can cause clinically significant interaction with substrates of CYP1A2, CYP2C8, CYP2C9, CYP2C19 and CYP2D6, however, after a single dose of the drug, concentrations that can cause inhibition of the activity of the studied enzymes are not reached. The possibility of adjusting the pharmacological effects of propoxazepam with flumazenil has been shown. In general, propoxazepam does not cause significant pharmacokinetic and pharmaceutical interactions with a single dose, although further studies are needed to assess the potential for inhibition of CYP enzymes and the impact on pharmacological effects with chronic use.  Product Description popup.authors Artemenko Anatolii H. Burenkova Nataliia O. Valivodz Iryna P. Holovenko Mykola Ya. Kichova Mariia Ye. Larionov Vitalii B. Ohnichenko Liudmyla M. Khromov Oleksandr I. Tsapenko Zhanna М. popup.nrat_date 2024-12-27 Close
R & D report
Head: Holovenko Mykola Ya.. Determining the safety of the innovative analgesic propoxazepam in its chemical and biological interactions with other drugs in polytherapy. (popup.stage: 2. Визначення хімічних та фізико-хімічних властивостей субстанції пропоксазепаму, необхідних для інтерпретації фармацевтичної взаємодії.). Physico-Chemical Institute O. Bogatsky National Academy of Sciences of Ukraine. № 0224U033461
1 documents found

Updated: 2026-03-21